Commercially, this creates a new reality for oncology manufacturers. Value erosion is no longer a single end-of-life event, but a two-step curve governed by policy-driven price resets and competitive erosion. The historical reliance on long post-approval tails, sequential indication expansion, and incremental lifecycle extensions is becoming less predictable and, in some cases, economically untenable. As a result, oncology strategy is shifting upstream. Portfolio prioritization, earlier evidence generation, tighter launch sequencing, and access planning must now account for a compressed value horizon, raising the stakes on early differentiation and forcing sharper tradeoffs in how, where, and when companies invest to sustain growth under increasing pricing pressure. Although the IRA introduces meaningful affordability benefits for Medicare beneficiaries, these gains coincide with operational, financial, and strategic strain across manufacturers, payers, and healthcare providers.

IRA-Driven Impact Across the Healthcare Ecosystem

The IRA reshapes oncology economics by changing how pricing, reimbursement, and affordability interact across the care ecosystem. These shifts alter incentives for every stakeholder, creating downstream implications that manufacturers must anticipate as pricing pressure increasingly impacts the chain of payers, providers, and patients.

• Manufacturers: IRA pricing arrives earlier, so the revenue runway is shorter and lifecycle strategy has to move forward in time. As a result, value creation is increasingly pulled forward, with biopharma reassessing not only lifecycle investment decisions but also the timing of external growth. The IRA further creates an uneven market dynamic, where large biopharma can accelerate parallel indication stacking, early multi-tumor strategies, and earlier acquisitions or partnerships to maximize value within a shortened commercial window; while smaller/emerging players, constrained by funding, face fewer opportunities to mitigate shortened revenue horizons. Across the board, this forces earlier value creation, sharper portfolio prioritization, and more disciplined lifecycle investment decisions.
• Payers: Benefit redesign increases plan liability and raises the sensitivity to total regimen cost, not just unit price. Oncology Part D plan liability is projected to be roughly 10 times higher in 2025 than in 2024 as patients move more quickly into catastrophic coverage. Manufacturers will need earlier proof that outcomes and regimen choices reduce avoidable spend, supported by real-world evidence and clear contracting logic, as payers actively manage risk in a higher liability oncology environment.
• Providers & Health System: Reimbursement pressure, particularly for physician-administered therapies, continues to challenge practice economics and is accelerating the consolidation of independent oncology practices into larger health systems and community networks. As scale becomes a prerequisite for financial viability, provider decision-making is increasingly centralized, with implications for site of care, treatment pathways, and adoption dynamics. Success now depends not only on individual physician engagement, but on understanding how consolidated provider models shape access, utilization, and economic sustainability across care settings.
• Patients: The IRA offers significant benefit for Medicare patients as out-of-pocket caps improve affordability and reduce financial burden on patients reliant on high-cost therapies. While this may support utilization and adherence, it occurs within a more tightly managed access environment that shifts differentiation toward care experience and support.

Collectively, these dynamics create a more interconnected and constrained oncology market, where pricing, access and adoption are tightly linked, and commercial advantage depends on navigating the full ecosystem rather than any single stakeholder in isolation.

The Looming LoE Wave for High-Spend Oncology Products

The oncology market is approaching one of the most significant LoE-driven patent cliffs in its history, with a concentrated set of high revenue therapies expected to face generic or biosimilar competition over a relatively short period. This convergence reflects the rapid approval and uptake of targeted therapies and immune-oncology agents in the mid-2010s, which, while accelerating patient access, also aligned exclusivity timelines across many of today’s largest oncology brands. As a result, products that have anchored oncology growth for the past decade are now approaching competitive erosion nearly simultaneously.

The scale and timing of this LoE wave have heightened both revenue risk and competitive intensity. Historically, major oncology blockbusters have experienced sharp and rapid erosion following loss of exclusivity, and the breadth of today’s portfolios suggests the upcoming cliff may be even more disruptive. Companies with diversified pipelines and multiple growth drivers are better positioned to absorb this impact, while those reliant on a small number of flagship assets face disproportionate exposure as pricing power diminishes and competition accelerates.

Critically, this LoE wave does not occur in isolation. When layered on top of earlier policy-driven pricing pressure, loss of exclusivity transforms from a late lifecycle event into part of a broader, multi-stage erosion curve. For oncology manufacturers, this compresses the window for revenue realization and heightens the need for broader portfolio balance, proactive lifecycle management, and earlier strategic investment as major immunotherapy backbones approach exclusivity loss.

Anti-PD-1 LoE as an Inflection Point in Oncology Economics

The impending LoE for anti-programmed cell death protein 1 (PD-1) therapies represents a defining inflection point for oncology economics. Few drug classes have reshaped cancer care as profoundly or achieved comparable scale. Broad tumor applicability, extensive line of therapy use, and rapid indication expansion established PD-1s programmed death-ligand 1 (PD-L1s) as foundational backbones across oncology, anchoring both treatment paradigms and revenue growth for much of the past decade.

Despite an increasingly crowded space, the market is dominated by the duopoly of Keytruda and Opdivo, capturing ~80% of PD-1/PD-L1 sales volume since 2020. As these therapies approach LoE in 2028, the impact extends far beyond revenue erosion for individual brands. PD-1 commoditization fundamentally alters the economic architecture of oncology treatment, shifting value away from the backbone itself and towards combination partners, add-on agents, and differentiated mechanisms.

Lower cost anti-PD-1s may expand access and utilization, but they do not necessarily reduce the total cost of care. As PD‑1s increasingly function as baseline components of multi‑drug regimens, overall regimen costs will be driven by the incremental therapies layered on top, often novel, premium‑priced agents. In this environment, payer scrutiny is likely to intensify, with greater emphasis on whether combination regimens deliver meaningful incremental benefit relative to their added cost. The perceived “value of innovation” will depend less on the backbone and more on the clinical contribution, durability of response, and system‑level impact of the new therapy itself.

As a result, relying on association with an anti-PD-1 backbone to justify premium positioning becomes more difficult. Even in a post-exclusivity landscape, new agents will still be required to clearly demonstrate their value, both clinically and economically, within increasingly complex treatment regimens. For originators and competitors alike, this moment accelerates the need for portfolio diversification, sharper lifecycle optimization, and a redefinition of how value is created and sustained in a post PD-1 oncology market.

Bottom Line

Oncology’s commercial model is undergoing a structural reset. Earlier pricing intervention, a concentrated loss of exclusivity wave, and the impending commoditization of foundational therapies are collectively compressing value horizons and raising the bar for sustained growth. Responding to this shift will require tighter alignment across R&D, access, commercial, and portfolio governance to enable earlier, more coordinated decisions and greater precision in how value is created and protected. The historical playbook of premium pricing supported by long post-approval expansion is giving way to a market where value must be established earlier, defended more deliberately, and extended through portfolio-level strategy rather than individual assets alone. Strategic imperatives for pharma leaders to consider include:

• Create value earlier in the lifecycle: Compressed commercial runways demand front-loaded differentiation, with evidence, pricing, and access strategy aligned well before launch rather than optimized after approval. Science alone does not win in the dynamic commercial market.
• Be more selective with post-approval investment: Sequential indication expansion and incremental lifecycle extensions face greater economic scrutiny, forcing sharper prioritization of high-impact opportunities.
• Plan for multi-stage erosion, not single cliffs: Policy-driven price resets, followed by loss of exclusivity, require earlier portfolio diversification and proactive lifecycle defense. The increased cost of running parallel Phase I-III clinical trials can mean important tradeoffs in research and development need to be made.
• Prepare for backbone commoditization: As cornerstone therapies lose exclusivity, differentiation shifts decisively to combinations, add-on agents, and outcomes that demonstrate incremental system value. At the same time, declining backbone costs may reshape cost-effectiveness models, altering how incremental innovation is valued.
• Elevate access and ecosystem strategy: Success increasingly depends on navigating payer management, provider economics, and site-of-care dynamics, not just clinical performance.
• Use M&A as a strategic necessity: Acquisitions and partnerships become essential to offset compressed lifecycles, rebuild growth engines, and maintain relevance in a cost-constrained oncology market.

Ultimately, the next phase of oncology will reward companies that adapt early, align strategy across the full ecosystem, and treat access, evidence, and portfolio design as integrated levers of long-term commercial advantage—not downstream considerations. Contact IQVIA to learn more about how to accelerate value creation and build access strategies in an era of economic compression for the oncology market.